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Abstract
Background Genetic heterogeneity is common in in-
herited cardiac diseases. Next-generation sequencing
gene panels are therefore suitable for genetic diagno-
sis. We describe the results of implementation of car-
diomyopathy and arrhythmia gene panels in clinical
care.
Methods We present detection rates for variants with
unknown (class 3), likely (class 4), and certain (class 5)
pathogenicity in cardiogenetic gene panels since their
introduction into diagnostics.
Results In 936 patients tested on the arrhythmia
panel, likely pathogenic and pathogenic variants were
detected in 8.8% (4.6% class 5; 4.2% class 4), and
one or multiple class 3 variants in 34.8%. In 1970
patients tested on the cardiomyopathy panel, likely
pathogenic and pathogenic variants were detected
in 19.8% (12.0% class 5; 7.9% class 4), and one or
multiple class 3 variants in 40.8%. Detection rates
of all different classes of variants increased with the
increasing number of genes on the cardiomyopa-
thy gene panel. Multiple variants were detected in
11.7% and 28.5% of patients on the arrhythmia and
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cardiomyopathy panels respectively. In more recent
larger versions of the cardiomyopathy gene panel the
detection rate of likely pathogenic and pathogenic
variants only slightly increased, but was associated
with a large increase of class 3 variants.
Conclusion Overall detection rates (class 3, 4, and
5 variants) in a diagnostic setting are 44% and 61%
for the arrhythmia and cardiomyopathy gene panel
respectively, with only a small minority of likely
pathogenic and pathogenic variants (8.8% and 19.8%
respectively). Larger gene panels can increase the
detection rate of likely pathogenic and pathogenic
variants, but mainly increase the frequency of vari-
ants of unknown pathogenicity.
Keywords Next-generation sequencing · Variants of
unknown significance · Cardiogenetic · Gene panel ·
Detection rate
What’s new?
 Overall detection rate of likely pathogenic and
pathogenic variants and variants of unknown
significance using large diagnostic gene pan-
els is 61% and 44% for cardiomyopathies and
primary arrhythmia syndromes respectively.
 The majority of detected variants in cardio-
genetic gene panels is still classified as variant
of unknown significance.
 Larger gene panels can increase the detection
rate of pathogenic variants, but mainly in-
crease the frequency of variants with unknown
pathogenicity and of multiple variants.
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Introduction
Next-generation sequencing (NGS) techniques with
sequencing and analysis of multiple genes in a single
experiment are being used more frequently in a diag-
nostic setting in monogenic diseases. Examples are
whole exome sequencing (WES) and disease-specific
gene panels which can be complemented by Sanger
sequencing to cover the entire coding region of the
specified genes. Gene panels are particularly well
suited in genetic heart diseases, because of their phe-
notypic and genetic heterogeneity; a single disease
associated with different genes, and a single gene
associated with different diseases [1].
Testing more genes using a gene panel not only in-
creases the detection rate of disease-causing variants,
but also of so-called variants of uncertain/unknown
significance (VUS). VUS are variants whose implica-
tion with disease cannot be concluded based on cur-
rent data. With time and further knowledge, VUS can
then be classified as either benign without clinical sig-
nificance or disease-causing.
This article shows the yield of pathogenic variants
and VUS of cardiogenetic gene panels for primary ar-
rhythmia syndromes and cardiomyopathies used in
a diagnostic setting. A separate article describes the
challenges for counselling and clinical decision mak-
ing that can arise from unclear gene panel results.
Table 1 Genes included in the gene panels
Gene panel Genes Patients tested (n)
Arrhythmia panel version 1 (43 genes) ABCC9, AKAP9, ANK2, CACNA1C, CACNA1D, CACNA2D1, CACNB2,
CALM1, CALM2, CALM3, CASQ2, CAV3, DPP6 (only position c.-340),
GJA5, GPD1L, HCN4, KCNA5, KCND3, KCNE1, KCNE1L, KCNE2, KCNE3,
KCNH2, KCNJ2, KCNJ5, KCNJ8, KCNQ1, LAMP2, LMNA, NPPA, PKP2,
PLN, PRKAG2, RANGRF, RYR2, SCN1B, SCN3B, SCN4B, SCN5A,
SNTA1, TNNT2, TRDN, TRPM4
170
Arrhythmia panel version 2 (47 genes) Version 1+ ASPH, JPH2, SCN2B, SLMAP 90
Arrhythmia panel version 3 (48 genes) Version 2+ SCN10A 308
Arrhythmia panel version 4 (49 genes) Version 3+ NKX2-5 199 (150 incl. CNV)
Arrhythmia panel version 5 (50 genes) Version 4+ PPA2 172
Cardiomyopathy panel version 1 (23 genes) ACTC1, CSRP3, DES, EMD, GLA, LAMP2, LDB3, LMNA, MYBPC3,
MYH7, MYL2, MYL3, PLN, PRKAG2, SCN5A, SGCDa, TAZ, TCAP,
TNNC1, TNNI3, TNNT2, TPM1, VCL
325
Cardiomyopathy panel version 2 (41 genes) Version 1+ ACTN2, ANKRD1, BAG3, CALR3, CAV3, CRYAB, DSC2,
DSG2, DSP, FHL1, JPH2, JUP, MYH6, MYOZ2, MYPN, PKP2, RBM20,
TMEM43, TTR
261
Cardiomyopathy panel version 3 (46 genes) Version 2+ CTNNA3, LAMA4, MIB1, NEXN, PRDM16 188
Cardiomyopathy panel version 4 (47 genes) Version 3+ TTN 347
Cardiomyopathy panel version 5 (50 genes) Version 4+ ALPK3, FHL2, HCN4 603 (206 incl. CNV)
Cardiomyopathy panel version 6 (53 genes) Version 5+ CDH2, FLNC, PPA2 246
CNV (copy number variant) analysis was added to the gene panels in January 2017. Thus, not all patients analysed on the arrhythmia panel version 4 and
cardiomyopathy panel version 5 have had CNV analysis
aThe SGCD gene was removed from the cardiomyopathy panels version 2 and 3 because of inadequate evidence that the gene is associated with cardiomy-
opathies
Methods
Study population and clinical evaluation
Data were collected from molecular diagnostics of
all probands (first patient in their family) in whom
a gene panel was performed at the DNA laboratory of
Amsterdam UMC, University of Amsterdam. Patients
were included from the introduction of gene panels
in diagnostic settings (arrhythmia panel: November
2013; cardiomyopathy panel: February 2012) until
January 1, 2018. Patients mainly came from the de-
partments of Clinical Genetics of Dutch University
hospitals.
In 2,829 probands, genetic testing was performed
using the gene panels: 936 probands on the arrhyth-
mia gene panel, 1970 on the cardiomyopathy gene
panel and 77 on both panels. The results of a few
patients have been published before [2]. Almost all
panel requests came from clinical geneticists spe-
cialised in cardiogenetics. We collected data on (sus-
pected) clinical diagnosis from the DNA request form:
hypertrophic cardiomyopathy (HCM), dilated car-
diomyopathy (DCM), arrhythmogenic (right ventric-
ular) cardiomyopathy (ARVC), noncompaction car-
diomyopathy (NCCM), unspecified cardiomyopathies
(UCM), long QT syndrome (LQTS), Brugada syndrome
(BRS), cathecholaminergic polymorphic ventricular
tachycardia (CPVT), unspecified arrhythmia (UA) and
other indications (ventricular fibrillation, ventricular
tachycardia, sudden cardiac death, conduction dis-
orders). Not all patients fulfil diagnostic criteria for
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the disease as suspicion can be enough reason to be
tested. It is beyond the scope of this study to include
detailed clinical data of evaluated patients. All pa-
tients gave informed consent for the anonymous use
of their genetic data.
Next-generation sequencing (NGS) gene panels
Detailed information on NGS, the platforms used and
their analytical performance has been published be-
fore and is described in the online Supplementary
File 1 [2, 3]. Tab. 1 shows the genes in the differ-
ent versions of the arrhythmia and cardiomyopathy
panels.
Variants are reported using Human Genome Vari-
ation Society nomenclature guidelines (http://www.
hgvs.org/mutnomen) and classified into one of five
categories (class 1: certainly not pathogenic, class 2:
unlikely pathogenic, class 3: unknown pathogenic-
ity, class 4: likely pathogenic; class 5: (certainly)
pathogenic) using the classification criteria as indi-
cated in the online Supplementary File 1. Identified
class 1 and 2 variants are not reported. Classification
was carried out at the moment the sequence data
were analysed using the data available at that time.
Reinterpretation and reclassification was only done
when the variant was detected in another patient or
more information became available from the family
or other cases in other clinical genetics centres in the
Netherlands.
Statistical analysis
Variables are reported as frequency (%). Categori-
cal and dichotomous variables are compared between
groups using the chi-squared test. A two-sided p-
Table 2 Detected variants since 2015 per diagnosis category
Diagnosis Patients Variants Highest pathogenicity class Multiple Additional information
Total Class 5 Class 4 Class 3
In the arrhythmia gene panel in 572 patients with the most common indications
Brugada syndrome 42 24 (57.1%) 4 (9.5%) 0 (0%) 23 (54.8%) 13
LQTS 65 35 (53.8%) 7 (10.8%) 5 (7.7%) 23 (35.4%) 11
CPVT 38 23 (60.5%) 0 (0%) 5 (13.2%) 18 (47.4%) 8
SCA/SCD 6 2 (33.3%) 0 (0%) 0 (0%) 2 (33.3%) 0
UA 421 190 (45.1%) 17 (4.0%) 16 (3.8%) 155 (36.8%) 48 Two with risk factor
(c.253G> A; p.(Asp85Asn) in
KCNE1)
In the cardiomyopathy gene panel in 1,281 patients with the most common indications
HCM 453 319 (70.4%) 70 (15.5%) 27 (6.0%) 222 (49.0%) 184
DCM 396 271 (68.4%) 28 (7.1%) 37 (9.3%) 206 (52.0%) 138
NCCM 67 44 (65.7%) 7 (10.4%) 5 (7.5%) 32 (47.8%) 21
ARVC 113 75 (66.3%) 19 (16.8%) 6 (5.3%) 50 (44.2%) 36
UCM 252 166 (65.9%) 22 (8.7%) 18 (7.1%) 126 (50.0%) 86
LQTS long QT syndrome, CPVT cathecholaminergic polymorphic ventricular tachycardia, SCA/SCD sudden cardiac arrest/sudden cardiac death, UA unspecified
arrhythmia, HCM hypertrophic cardiomyopathy, DCM dilated cardiomyopathy, NCCM noncompaction cardiomyopathy, ARVC arrhythmogenic right ventricular
cardiomyopathy, UCM unspecified cardiomyopathies
value of <0.05 was considered significant. SPSS (ver-




In 412 of the 936 (44.0%) patients analysed for the
arrhythmia gene panel one or more variants were
detected (detailed information in Tab. 2 and online
Supplementary File 2). Forty-three patients (4.6%)
had a pathogenic (class 5) variant, 39 (4.2%) a likely
pathogenic (class 4) variant, and 326 (34.8%) had
≥1 class 3 variants. Four patients carried a genetic
risk factor (c.253G>A; p.(Asp85Asn)) in KCNE1. This
specific KCNE1 variant has an allele frequency of ~1%,
but is known to be associated with LQTS [4]. The
82 pathogenic variants (including likely pathogenic)
were detected in 16 different genes. Multiple variants
were detected in 11.8% of patients, with a maximum
of four variants in a single patient.
Cardiomyopathy gene panel
In 1,194 of the 1970 (60.8%) patients analysed for the
cardiomyopathy gene panel, one or more variants
were detected (detailed information in Tab. 2 and
online Supplementary File 2). 236 patients (12.0%)
had a pathogenic variant, 155 (7.9%) ≥1 class 4 vari-
ants and 803 (40.8%) ≥1 class 3 variants. The 391
pathogenic variants (including likely pathogenic) were
detected in 34 different genes. Multiple variants were
detected in 28.5% of patients with a maximum of
seven variants in a single patient.
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Table 3 Yield of the ar-
rhythmia and cardiomyopa-
thy gene panel before and
after 2015
Pathogenicity class Number of variants< 2015 Number of variants≥ 2015
Arrhythmia gene panel
Class 5 10 (3.9%) 22 (3.2%)
Class 4 11 (4.2%) 28 (4.1%)
Class 3 74 (28.2%) 252 (37.2%)
Risk factor 2 (0.8%) 2 (0.3%)
No variants reported 164 (63.3%) 375 (55.4%)
Cardiomyopathy gene panel
Class 5 86 (11.1%) 150 (12.5%)
Class 4 58 (7.5%) 97 (8.1%)
Class 3 179 (23.2%) 624 (52.1%)
No variants reported 450 (58.2%) 326 (27.2%)
Yield and gene panel size
Yield of all different classes of variants, but mainly
class 3, increased when more genes were analysed on
the panel. There was a significant increase in yield of
class 3 variants before and after 2015 (including the
TTN gene since 2015 in the cardiomyopathy panel)
for the arrhythmia panel (χ2(2)= 25,133; p< 0.01) and
cardiomyopathy panel (χ2(2)= 633,987; p<0.01), but
not of class 4 and 5 variants (Tab. 3).
To see if larger gene panels perform better than
small disease-specific panels for 508 patients with
(suspected) HCMwe compared the yield of class 4 and
5 variants of our cardiomyopathy gene panel with that
of a fictive gene panel of seven genes with a clear as-
sociation with HCM (MYBPC3, MYH7, TNNT2, TNNI3,
TPM1, MYL2, MYL3). In 172 HCM patients a class 4/5
variant was detected. Using this fictive gene panel we
would have missed 9 of 122 class 5 variants and 19 of
50 class 4 variants. The fictive gene panel would yield
28.3% class 4/5 variants instead of 33.9% (p= 0.0672).
Dutch founder variants
In the Netherlands, several variants have been de-
tected more frequently. For many of these variants
haplotype analysis and genealogy suggest the variant
originates from an ancient founder. In 100 patients
a previously described founder variant was detected
and in 81 another recurrent variant (online Supple-
mentary File 3). Founder variants and recurrent vari-
ants made up 34.9% of class 5 variants in the arrhyth-
mia panel and 70.3% of class 5 variants in the car-
diomyopathy panel.
Variant reclassification
We looked at reclassification of variants that occurred
between January 1, 2015 and January 1, 2018, based
on reinterpretation. Most variants were not reclas-
sified at reinterpretation. For the arrhythmia panel
seven variants were reclassified and for the cardiomy-
opathy panel 13 (upgrade of pathogenicity class in 9,
downgrade in 11). Reasons for reclassification were
new information on frequency of the variant in con-
trol databases (n= 6), results of RNA studies (n= 5),
co-segregation in the family (n= 5) and additional pa-
tients/families with the same variant (n= 4) (online
Supplementary File 2).
Discussion
Overall detection rate (class 3, 4, and 5 variants) is
44% and 61% for the arrhythmia and cardiomyopa-
thy panels respectively, with only a minority of likely
pathogenic and pathogenic variants (8.8% and 19.8%
respectively). These yields of likely pathogenic and
pathogenic variants are lower than published in pre-
NGS literature [5–9] and NGS literature (data≥ 2015:
HCM: 21.4% class 4/5 variants in our cohort vs 32% in
literature [10]; DCM: 16.3% class 4/5 variants in our
cohort vs 37% in literature [11]; Brugada syndrome:
9.5% class 4/5 variants in our cohort vs ~20% in lit-
erature [7, 12]). Even the substantial contribution of
Dutch founder variants does not raise detection rates.
There are several explanations for this. First, indica-
tions for diagnostic DNA testing broadened in the past
years. It is no longer only patients meeting diagnostic
criteria for disease, such as the well-phenotyped re-
search cohorts from literature, who are being tested.
A study of our centre also showed decreasing yields
in time explained by patients with less severe phe-
notypes being tested in more recent years [13], and
studies have been published confirming that yield is
higher in more severe patients [14]. Increased aware-
ness of genetic heart disease also gives rise to more
referrals of patients with a merely suspected personal
or family history of disease. An unclear phenotype
is a likely explanation for the lower yield of the ar-
rhythmia panel, as, for example, sudden cardiac ar-
rest or sudden cardiac death could also have non-
monogenic and/or non-cardiac causes (Tab. 2). Pa-
tients with a clear diagnosis of LQTS or CPVT, for
which a small set of genes can be tested with a high
pathogenic yield, are underrepresented in the arrhyth-
mia panel cohort. Second, standards for calling a vari-
Large next-generation sequencing gene panels in genetic heart disease: yield of pathogenic variants and. . . 307
Original Article
ant pathogenic have become more stringent. The
difference between likely pathogenic and pathogenic
was almost absent in early years. Any rare evolu-
tionary conserved variant not found in ~100 healthy
controls was considered pathogenic. Third, inher-
ited cardiac diseases are relatively common and show
incomplete and age-dependent penetrance, meaning
that also pathogenic variants or modifiers can be de-
tected in control databases and can have a relatively
high frequency in the general population. Presence
of a variant in control databases therefor does not
exclude pathogenicity. Whereas for highly penetrant,
rare diseases low-frequency variants are labelled likely
benign or benign (class 1 or 2 variant), for cardiac dis-
eases they will be classified as unknown pathogenic-
ity (class 3 variant). Fourth, knowledge on many of
the genes on the panels and variant classification in
these genes is sparse, because clear disease associa-
tions have been made in a few patients. Variants are
therefore easily classified as a type 3 variant.
The increasing number of genes on different ver-
sions of our cardiomyopathy panel did result in
a higher detection rate of likely pathogenic and
pathogenic variants, but mainly of class 3 variants.
This has been shown previously in literature [10, 11,
15]. A lower number of tested genes makes inter-
pretation of test results easier, with less VUS, but
also increases the risk of missing pathogenic variants.
The addition of the TTN gene to the cardiomyopathy
panel in 2015 only resulted in an increase of class 4
and 5 variants in the DCM patients, but not in other
cardiomyopathy patients. In all patients, however,
the addition of TTN resulted in an increase of class 3
variants. This can, however, also be the result of less
severe patients being tested in more recent years. De-
velopments in diagnostic DNA testing and increasing
knowledge on tolerated DNA variants ask for con-
tinuous re-evaluation of which test (single genes or
large panel) or which filter used for a genome-wide
test is best suited for which patient. Initiatives like
ClinGen (www.clinicalgenome.org), which evaluates
clinical validity of supposed disease genes, can be
of help with this, and possibly patients can make an
informed choice in the extent of the DNA test and
the given results. Although reclassification was un-
common on reinterpretation in our cohort, updates
of classification status of class 3–5 variants should
be made regularly, including reporting important re-
classifications back to the physician who requested
the test. Initiatives that allow sharing of variant data
could help in solving the meaning of observed VUS.
Multiple variants were detected in 11.8% and 28.5%
of patients on the arrhythmia and cardiomyopathy
panels respectively. Some variants will eventually be
classified as benign variants, but others will be associ-
ated with disease. Although inherited cardiac diseases
are considered to follow an autosomal dominant in-
heritance pattern, the presence of multiple variants in
our study, and previous descriptions of multiple rare
variants, digenic inheritance, homozygous and com-
pound heterozygous variants, all suggest more com-
plex inheritance patterns and modifier effects [16–19].
This might also explain the variable disease expression
of inherited cardiac diseases.
The high frequency of VUS in cardiogenetic gene
panels necessitates pre-test counselling on VUS of
tested patients. However, incidental findings can still
give rise to challenges in counselling/clinical decision
making. In a separate article we describe these chal-
lenges in more detail. We recommend pre-test and
post-test counselling to be performed by a physician/
counsellor with sufficient knowledge on VUS and
variant classification. Challenging cases should be
discussed in a multidisciplinary cardiogenetics team.
Conclusions
Overall detection rates for cardiogenetic NGS gene
panels in a diagnostic setting are 44% and 61% for the
arrhythmia and cardiomyopathy gene panels respec-
tively, with only a small minority of likely pathogenic
and pathogenic variants (8.8% and 19.8% respec-
tively). Larger gene panels can increase detection
rates of likely pathogenic and pathogenic variants,
but mainly increase the frequency of VUS. Test re-
sults, especially VUS and incidental findings, can be
challenging for genetic counselling and ask for proper
pre-test and post-test counselling and evaluation by
a multidisciplinary cardiogenetics team.
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